Chugai Pharmaceutical Co (JP:4519) has released an update. Chugai Pharmaceutical Co. has reported a strong financial performance for the first nine months of 2024, with a 3.7% increase in revenue ...
said Chugai. The approval is based on the results of the single-arm COMMODORE-3 trial, carried out within China, along with the comparative COMMODORE-2 study, which showed that crovalimab was as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback